MedTrace Logo

GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L)

NCT01497665 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2019-01-22

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the efficacy, safety, and tolerability of GRN1005 in patients with brain metastases from non-small cell lung cancer (NSCLC).

Conditions

  • Non-small Cell Lung Cancer (NSCLC) With Brain Metastases

Interventions

DRUG

GRN1005

650 mg/m2 IV every 3 weeks

Sponsors & Collaborators

  • Angiochem Inc

    lead INDUSTRY

Principal Investigators

  • Betty Lawrence · Angiochem Inc

  • Patrick Wen, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2013-01-31
Completion
2013-02-28

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01497665 on ClinicalTrials.gov